These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality. Waddington JL; Youssef HA; Dolphin C; Kinsella A Arch Gen Psychiatry; 1987 Oct; 44(10):907-12. PubMed ID: 2889438 [TBL] [Abstract][Full Text] [Related]
23. Tardive dyskinesia in bipolar affective disorder: relationship to lithium therapy. Dinan TG; Kohen D Br J Psychiatry; 1989 Jul; 155():55-7. PubMed ID: 2575003 [TBL] [Abstract][Full Text] [Related]
24. Factors related to the severity of tardive dyskinesia. Wade JB; Hart RP; Dougherty LM Brain Cogn; 1993 Sep; 23(1):71-80. PubMed ID: 8105823 [TBL] [Abstract][Full Text] [Related]
25. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. Kane JM J Clin Psychiatry; 2004; 65 Suppl 9():16-20. PubMed ID: 15189107 [TBL] [Abstract][Full Text] [Related]
26. Involuntary orofacial movements in hospitalised patients with mental handicap or epilepsy: relationship to developmental/intellectual deficit and presence or absence of long-term exposure to neuroleptics. Youssef HA; Waddington JL J Neurol Neurosurg Psychiatry; 1988 Jun; 51(6):863-5. PubMed ID: 2900294 [TBL] [Abstract][Full Text] [Related]
27. Postural stability, tardive dyskinesia and developmental disability. Ko YG; Van Emmerik RE; Sprague RL; Newell KM J Intellect Disabil Res; 1992 Aug; 36 ( Pt 4)():309-23. PubMed ID: 1356038 [TBL] [Abstract][Full Text] [Related]
28. Cognitive dysfunction in schizophrenia: organic vulnerability factor or state marker for tardive dyskinesia? Waddington JL; O'Callaghan E; Larkin C; Kinsella A Brain Cogn; 1993 Sep; 23(1):56-70. PubMed ID: 8105822 [TBL] [Abstract][Full Text] [Related]
29. Association of negative symptoms with tardive dyskinesia in schizophrenic patients. Chiu H; Lau J; Lam L; Shum P Aust N Z J Psychiatry; 1993 Jun; 27(2):228-32. PubMed ID: 8103320 [TBL] [Abstract][Full Text] [Related]
31. Informing patients about tardive dyskinesia: four-year follow up of a trial of patient education. Chaplin R; Timehin C Aust N Z J Psychiatry; 2002 Feb; 36(1):99-103. PubMed ID: 11929445 [TBL] [Abstract][Full Text] [Related]
33. Episodic tardive dyskinesia and parkinsonism in bipolar disorder patients. Scappa S; Teverbaugh P; Ananth J Can J Psychiatry; 1993 Dec; 38(10):633-4. PubMed ID: 7906192 [TBL] [Abstract][Full Text] [Related]
34. Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia. Rapaport A; Sadeh M; Stein D; Levine J; Sirota P; Mosheva T; Stir S; Elitzur A; Reznik I; Geva D; Rabey JM Mov Disord; 2000 Mar; 15(2):352-5. PubMed ID: 10752596 [No Abstract] [Full Text] [Related]
35. Tardive dyskinesia in bipolar affective disorder: aging, cognitive dysfunction, course of illness, and exposure to neuroleptics and lithium. Waddington JL; Youssef HA Am J Psychiatry; 1988 May; 145(5):613-6. PubMed ID: 2895985 [TBL] [Abstract][Full Text] [Related]
36. The psychological consequences of tardive dyskinesia. The effect of drug-induced parkinsonism and the topography of the dyskinetic movements. Brown KW; White T Br J Psychiatry; 1991 Sep; 159():399-403. PubMed ID: 1683594 [TBL] [Abstract][Full Text] [Related]